Summary & Overview
HCPCS Q5144: Adalimumab‑aacf (Idacio) Injection, 1 mg
HCPCS Level II code Q5144 designates the biosimilar injectable product adalimumab-aacf (Idacio) in a 1 mg unit. This code matters nationally as biosimilar adoption influences biologic drug spend, access to treatment for autoimmune conditions, and payer coverage policies across commercial and public programs. HCPCS coding ensures consistent reporting of administered drug products for reimbursement, pharmacy billing, and utilization tracking.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage and billing considerations for the product, how the code is used in outpatient injection settings, and the clinical context for adalimumab biosimilars. The publication summarizes standard billing practices, common modifier usage where available, and the implications of using a biosimilar HCPCS code for prior authorization and claims processing.
The article provides benchmarks and policy-relevant information to help billing managers, clinicians, and revenue cycle staff understand coding impact, anticipated payer behaviors, and operational considerations when administering and billing adalimumab-aacf (Idacio) using HCPCS Level II code Q5144. Data not available in the input.
Billing Code Overview
HCPCS Level II code Q5144 represents injection, adalimumab-aacf (Idacio), biosimilar, 1 mg. This code covers the drug product administered as an injectable biologic, with the service type classified as administered injectable medication.
The typical site of service for billing HCPCS Level II code Q5144 is outpatient settings where biologic injections are given, such as physician offices, hospital outpatient departments, and infusion or injection clinics. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with established moderate-to-severe rheumatoid arthritis presents to an outpatient infusion/ambulatory injection clinic for scheduled subcutaneous biologic therapy with the adalimumab biosimilar, idacio. The medication is billed per milligram using HCPCS Level II code Q5144 (Injection, adalimumab-aacf (idacio), biosimilar, 1 mg). The clinical workflow includes medication verification by a licensed nurse, informed consent confirmation, documentation of baseline vital signs and infection screening (temperature, review of tuberculosis and recent infection history), pre-filled syringe preparation or vial reconstitution if applicable, and subcutaneous administration in the clinic or observation area. The patient is observed for a short period for immediate injection reaction and provided with post-injection self-care instructions, scheduled for the next dose, and the encounter is documented in the medical record with lot number, expiration date, dose administered (mg), site of injection, and supervising provider.
Typical site of service is an outpatient clinic, physician office, or ambulatory injection center. This service may also occur in an ambulatory infusion center when given alongside other parenteral therapies.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard primary procedural service |